BioSpecifics Technologies Corp

BioSpecifics Technologies — Investor Presentation (October 2015)

23 slides from BioSpecifics Technologies's investor presentation, Oct 5, 2015

  1. Slide 1: Innovators in the development & commercialization of injectable collagenase

    Innovators in the development & commercialization of INJECTABLE COLLAGENASE —_—°—~. 7 BioSpecifics October 2015

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, Including statements regarding

  3. Slide 3: Company Overview

    Company Overview BioSpecifics (Nasdaq: BSTC) is a profitable biopharma company. Originator of collagenase based-therapies. Receives revenues from XIAFLEX® (collagenase clostridium histolyticum or CCH) milestones, royalties on net sales, mark-up on COGS and sublicense income by partner Endo. Future r

  4. Slide 4: Unlocking Vast Potential of CCH

    Unlocking Vast Potential of CCH First-in-class, minimally invasive nonsurgical treatment for conditions caused by collagen accumulation with limited current treatment options BioSpecifics has positive clinical results in 12 indications: Dupuytren’s contracture’ Frozen shoulder Scarred tendons Peyron

  5. Slide 5: XIAFLEX for Dupuytren's Contracture

    XIAFLEX for Dupuytren’s Contracture First, Effective Non-Surgical Treatment Option Collagen cord in hand causing one or more fingers to contract toward Definition & Key the palm Complications Limits range of motion and impairs quality of life Affects up to 7% of adults in the U.S. Pre- treatment: Po

  6. Slide 6: Commercial Highlights for DC

    Commercial Highlights for DC ~6,200 vials shipped 2Q15 vs. 5,092 in 2Q14 First commercial sale in Japan in September 2015 Updated U.S. label including recurrence and retreatment data approved in May 2015 MULTICORD U.S. label expansion approved in October 2014 Treatment of up to two contracture joint

  7. Slide 7: XIAFLEX for Peyronie's Disease

    XIAFLEX for Peyronie’s Disease First, Effective Non-Surgical Treatment Option Definition & Key Complications Source: Endo International, ple Inelastic collagen causing penile curvature; penis can bend at 90° angle during erection in severe cases Associated with increased pain, painful erections, pal

  8. Slide 8: Commercial Highlights for PD

    Commercial Highlights for PD ~6,900 vials shipped 2Q15 vs. 2,752 in 2Q14 Continued traction with certified physicians and new patients in Peyronie’s disease As of 6/30/15 there were ~2,100 certified physicians and “9,800 cumulative patients enrolled in the re-imbursement program In May 2015: The Ame

  9. Slide 9: XIAFLEX Pipeline Programs

    XIAFLEX Pipeline Programs Future Revenue-Generating Opportunities Frozen Shoulder Phase 2b to initiate by end of 2015* Syndrome Cellulite Phase 2b to initiate by end of 2015* Human Lipomat Phase 2 top-line results 1H16 Canine Pas Reh — : Lipoma indo has license for further development Uterine Positi

  10. Slide 10: CCH for Frozen Shoulder Syndrome

    CCH for Frozen Shoulder Syndrome Potential to be Only FDA Approved Nonsurgical Therapy Definition & Complications Inflammation and thickening of shoulder capsule due to collagen Limits range of motion of shoulder f Potential to be Only FDA Approved Nonsurgical Therapy Market Opportunity Source: Endo

  11. Slide 11: Phase 2b Study of CCH in Frozen Shoulder

    Phase 2b Study of CCH in Frozen Shoulder Double-blind, placebo-controlled study evaluating safety and . . efficacy in Stage 2 (frozen stage) unilateral idiopathic frozen shoulder Objective & Rationale _. . a . Phase 2b study based on positive, statistically significant results in Phase 2a study of 5

  12. Slide 12: Phase 2b Study Results of CCH in FSS

    Phase 2b Study Results of CCH in FSS Phase 2a Results lh Strong, similar drug effect for key measures including forward flexion, shoulder abduction, external and internal rotation across both Phase 2a and Phase 2b trials Similar CCH patient improvement in pain seen across both trials 6&8 8 Degree im

  13. Slide 13: CCH for Cellulite

    CCH for Cellulite Definition Significant Market Opportunity as First Nonsurgical Therapy Positive Top-line Results Reported from Phase 2a Study in 3Q14 Source: Endo Intemational, ple Skin dimpling as a result of collagen fibrous septae, occurring mainly on the buttocks, lower limbs, and abdomen Affe

  14. Slide 14: CCH for Cellulite

    CCH for Cellulite Positive Top-line Data from Phase 2a Study Top-line Data from Phase 2a Study Mid and high level CCH doses demonstrated statistically significant improvement in cellulite across all endpoints 68% of mid and high dose groups reported being “Satisfied” or “Very Satisfied” with treatme

  15. Slide 15: CCH for Human Lipomas

    CCH for Human Lipomas Phase 2 Opt-In Study Managed by BioSpecifics Encapsulated deposits of benign fatty tumors; detected as bulges enoRion under the skin Potential to be No FDA-approved pharmaceutical therapies available Only Approved Nonsurgical Therapy Surgery not practical for patients with mult

  16. Slide 16: Positive Phase Clinical Trial Results

    Positive Phase 2 Clinical Trial Results Open label, dose escalation Phase 2 trial: Statistically significant (p<0.0001) reduction in primary endpoint of visible surface area of lipoma as measured by caliper, combining all patients Patients in highest dose group (75% of commercial dose) achieved best

  17. Slide 17: CCH for Lipomas in Canines

    CCH for Lipomas in Canines Key Complications Potential to be Only Approved Nonsurgical Therapy Chien-804 Trial Results Lipomas can seriously restrict motion in older dogs Surgery can be risky due to the use of general anesthesia - especially for older dogs 1.7M dogs affected in the U.S. annually Bas

  18. Slide 18: CCH for Uterine Fibroids

    CCH for Uterine Fibroids Endo Encouraged by Results Reported to Date Les i ili le Definition & Lolly decreased fertility, ecco Key C licati miscarriage, heavy menstrual H ss ey Complications bleeding and frequent urination 2 a | 8 Potential to be Primary indication for am 025 050 400 200 . ollagenas

  19. Slide 19: Endo Partnership for Development and Commercialization of CCH

    Endo Partnership for Development and Commercialization of CCH >$62.9M Received to Date Future Payments Due to BioSpecifics from Endo Endo Opt-in Rights Milestone Payments from Endo Partnerships $62.9M received in licensing, sublicensing, milestone, COGS, and royalty payments as of June 30, 2015 Firs

  20. Slide 20: Corporate Highlights

    Corporate Highlights Vast opportunity for growth in revenues from XIAFLEX sales and approval of CCH in new indications Strong IP portfolio Long-term patent protection for injectable collagenase: Dupuytren’s Contracture: XIAFLEX has Drug product composition patent until 2028 and Biologic Exclusivity

  21. Slide 21: Consistently Profitable Annually

    Consistently Profitable Annually 1H15 Financial Highlights (unaudited) Cash and equivalents, and investments Income Statement Revenues Other income Costs and expenses Provision for income taxes Net income Earnings per share: Basic Diluted Shares used in computation of earnings per share: Basic Dilut

  22. Slide 22: Anticipated Upcoming Pipeline Milestones

    Anticipated Upcoming Pipeline ° Milestones Upcoming Pipeline Milestones Human . . Lipomast O Phase 2 placebo-controlled opt-in trial top-line results in 1H16 Boney Q Refining development plan eae Q Initiate Phase 2b trial by end of 2015* Cellulite O Initiate Phase 2b trial by end of 2015* alts Q End

  23. Slide 23: Innovators in the development & commercialization of injectable collagenase

    2 é \ a? Innovators in the development & commercialization of ‘INJECTABLE COLLAGENASE ee BioSpecifics October 2015

BioSpecifics Technologies — Investor Presentation (October 2015) on 6ix